explore -WSS

explore

author：entertainment 2025-08-12 06:43:11 - browse：23

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Researchers tackle phage therapy hurdles for wider adoption

WSS

Flagship Pioneering startup Sonata Therapeutics lays off 21

Use wet bulb globe temperature, not heat index, to protect workers

As AI regulations shape up, health tech startups beg for clarity

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Researchers tackle phage therapy hurdles for wider adoption

Flagship Pioneering startup Sonata Therapeutics lays off 21

entertainment

explore

hotspot

Activists slam private health insurers over coverage restrictions

New study raises questions about niacin and heart health

Drug repurposing or repositioning? The language matters

Use wet bulb globe temperature, not heat index, to protect workers

New air purifier tech could be key to improving indoor air quality

How to improve immunocompromised access to mAb treatments

As demand for Covid shots wanes, Moderna seeks its next success

New CMS data security rules will hurt Medicare, Medicaid research

At least 13 dead in Texas as scorching temps continue

Flagship Pioneering startup Sonata Therapeutics lays off 21

entertainment

Steward Health Care files for bankruptcy

Flagship Pioneering startup Sonata Therapeutics lays off 21

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

As AI regulations shape up, health tech startups beg for clarity

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Surprise medical billing ban raises prices elsewhere

hotspot

focus

explore

hotspot